HCM; aficamten; mavacamten; hypertrophic cardiomyopathy

Overview
Hypertrophic cardiomyopathy (HCM) is a clinically heterogeneous disease. Nevertheless, common underlying etiology can be identified among patients with HCM. In this educational program, three experts discuss the clinical characteristics and pathophysiology of HCM, challenges in the diagnosis and management, and therapeutic options for patients with HCM.

This course consists of 3 episodes. Watch all episodes, answer pre- and post-test questions, and start earning CME credits.
Program Highlights
This educational program consists of three presentations on hypertrophic cardiomyopathy (HCM).
Hypertrophic cardiomyopathy: What are the concerns? - Antonis Pantazis, MD – London, UK
- What are the concerns about HCM? Antonis Pantazis discusses common concerns among patients and healthcare professionals.
Diagnostic challenges for symptomatic obstructive HCM- Pablo García-Pavia, MD, PhD – Barcelona, Spain
- Pablo García-Pavia discusses the challenges in the diagnosis of symptomatic obstructive HCM. He highlights that the pathophysiology of HCM goes beyond LVH, and involves also changes to other structures in the heart.
Improving quality of life in patients with HCM - Carolyn Ho, MD – Boston, MA, USA
- Cardiac myosin inhibitors have emerged as disease-specific therapy for HCM, improving quality of life in patients with HCM. Carolyn Ho discusses recent clinical trials with these agents.
Instructions
- Watch the three lectures and answer the pre- and post-test questions
- Fill in the evaluation questions
- Download CME Certificate
For questions regarding this activity, please contact us at info@medconinternational.com.
Learning Objectives
- Describe the clinical characteristics of HCM
- Describe how to diagnose HCM
- Recognize the challenges with diagnosing LVOT obstruction in symptomatic patients
- Describe the mechanism of action of cardiac myosin inhibitors
- Discuss the results of recent clinical trials with cardiac myosin inhibitors in patients with HCM
Target Audience
This educational activity is designed for all healthcare professionals with an interest in management of patients with HCM.
Accreditation and Credit Designation Statements
This online course is accredited by the European Board for Accreditation of Continuing Education for Health Professionals (EBAC) for 1 hour of external CME credit.
Through an agreement between EBAC and the American Medical Association, physicians may convert EBAC External CME credits to AMA PRA Category 1 Credits™. Information on the process to convert EBAC credit to AMA credit can be found on the AMA website. Other health care professionals may obtain from the AMA a certificate of having participated in an activity eligible for conversion of credit to AMA PRA Category 1 Credit™.
Commercial Support
Funding for this educational program was provided by an unrestricted educational grant from Cytokinetics.
Disclaimer
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of PACE-cme.
System Requirements
- Supported Browsers (2 most recent versions):
- Google Chrome for Windows, Mac OS, iOS, and Android
  Apple Safari for Mac OS and iOS
  Mozilla Firefox for Windows, Mac OS, iOS, and Android
  Microsoft Edge for Windows
- Recommended Internet Speed: 5Mbps+
Publication Dates
Release Date: 29/11/2023
Expiration Date: 29/11/2025